Volkmar Gieselmann Selected Research

Metachromatic Leukodystrophy (Sulfatide Lipidosis)

7/2022	Extremely low arylsulfatase A enzyme activity does not necessarily cause symptoms: A long-term follow-up and review of the literature.
1/2021	Deletion of fatty acid amide hydrolase reduces lyso-sulfatide levels but exacerbates metachromatic leukodystrophy in mice.
1/2021	Brain cell type-specific endocytosis of arylsulfatase A identifies limitations of enzyme-based therapies for metachromatic leukodystrophy.
12/2020	Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor.
1/2020	Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction.
1/2019	Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
10/2017	Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A.
9/2015	Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.
7/2015	Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy.
2/2014	Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Volkmar Gieselmann Research Topics

Disease

42	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 07/2022 - 10/2002
24	Lysosomal Storage Diseases (Lysosomal Storage Disease) 07/2022 - 12/2002
18	Demyelinating Diseases (Demyelinating Disease) 01/2021 - 09/2003
4	Disease Progression 01/2021 - 01/2006
4	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 04/2009
4	Neoplasms (Cancer) 01/2019 - 02/2010
3	Gliosis 09/2015 - 07/2004
3	Neuroblastoma 02/2010 - 11/2005
2	Fatty Acid Hydroxylase-Associated Neurodegeneration 01/2021 - 01/2018
2	Hereditary Spastic Paraplegia 01/2021 - 01/2018
2	Inflammation (Inflammations) 01/2020 - 09/2008
2	Neuroinflammatory Diseases 09/2015 - 07/2015
2	Nervous System Diseases (Neurological Disorders) 02/2014 - 04/2009
1	Astrocytoma (Pilocytic Astrocytoma) 01/2021
1	Cognitive Dysfunction 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Starvation 01/2020
1	Ganglion Cysts (Ganglion) 01/2020
1	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 01/2019
1	Canavan Disease (Leukodystrophy, Spongiform) 10/2015
1	Globoid Cell Leukodystrophy (Krabbe Disease) 09/2015
1	Fibrosis (Cirrhosis) 04/2014
1	Breast Neoplasms (Breast Cancer) 11/2011
1	Oncogene Addiction 10/2011
1	Central Nervous System Diseases (CNS Diseases) 07/2011
1	Osteoarthritis 11/2010
1	Shock 11/2010
1	Blister (Bulla) 02/2010
1	Seizures (Absence Seizure) 01/2010
1	Mucolipidoses (Sialidosis) 03/2009
1	Ischemia 09/2008
1	Sphingolipidoses (Sphingolipidosis) 04/2008
1	Anaphylaxis (Anaphylactic Shock) 09/2007
1	Stroke (Strokes) 11/2006
1	Hypercholesterolemia 06/2006
1	Glioma (Gliomas) 12/2005
1	Paralysis (Palsy) 07/2005
1	Neurologic Manifestations (Neurological Manifestations) 05/2005
1	Body Weight (Weight, Body) 05/2005

Drug/Important Bio-Agent (IBA)

33	Cerebroside-Sulfatase (Arylsulfatase A)IBA 07/2022 - 01/2003
21	EnzymesIBA 01/2021 - 12/2002
18	Sulfoglycosphingolipids (Sulfatides)IBA 01/2021 - 09/2003
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2006
6	ArylsulfatasesIBA 12/2020 - 10/2002
4	Lysergic Acid Diethylamide (LSD)IBA 01/2019 - 04/2009
4	HydrolasesIBA 10/2017 - 04/2009
4	SphingolipidsIBA 05/2005 - 09/2003
2	GlycosphingolipidsIBA 01/2021 - 02/2011
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2018
2	ProteomeIBA 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2011
2	CytokinesIBA 07/2015 - 09/2008
2	Hyaluronic Acid (Hyaluronan)IBA 11/2010 - 02/2010
1	Myelin ProteinsIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020
1	Nerve Growth Factor (NGF)IBA 01/2020
1	Lysosomal Membrane ProteinsIBA 01/2019
1	N-acetylaspartate (N-acetyl aspartate)IBA 10/2015
1	aspartoacylaseIBA 10/2015
1	Psychosine (Galactosylsphingosine)IBA 09/2015
1	GalactosylceramidaseIBA 09/2015
1	Monocyte Chemoattractant ProteinsIBA 07/2015
1	InterleukinsIBA 07/2015
1	Simvastatin (Zocor)FDA LinkGeneric 07/2015
1	Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)IBA 07/2015
1	ChemokinesIBA 07/2015
1	Pharmaceutical PreparationsIBA 07/2015
1	Mannose (D-Mannose)IBA 04/2014
1	LectinsIBA 04/2014
1	Peptides (Polypeptides)IBA 02/2014
1	Apolipoproteins E (ApoE)IBA 02/2014
1	Polysaccharides (Glycans)IBA 07/2012
1	Tumor Biomarkers (Tumor Markers)IBA 11/2011
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 11/2011
1	CalponinsIBA 11/2011
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2011
1	psychosine-3'-sulfate esterIBA 02/2011
1	LipidsIBA 02/2011
1	SaposinsIBA 04/2009
1	Detergents (Detergent)IBA 04/2009
1	lysosomal proteinsIBA 04/2009
1	AntibodiesIBA 04/2008
1	Fructose-Bisphosphate Aldolase (Aldolase)IBA 11/2006
1	zebrin IIIBA 11/2006
1	CholesterolIBA 06/2006
1	Bisbenzimidazole (Hoechst 33258)IBA 12/2005
1	N-Acylsphingosine GalactosyltransferaseIBA 11/2005
1	Actins (F Actin)IBA 11/2005
1	Ganglioside GalactosyltransferaseIBA 07/2005

Therapy/Procedure

7	Enzyme Replacement Therapy 01/2021 - 04/2006
5	Therapeutics 01/2021 - 01/2006
4	Intravenous Injections 06/2012 - 09/2007
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2021 - 12/2002
1	Hematopoietic Stem Cell Transplantation 01/2020
1	Transplantation 01/2020
1	Cell Transplantation 01/2020
1	Viscosupplementation 11/2010
1	Injections 05/2005